Evercore ISI raises Illumina target to $200
Evercore ISI Group analyst Vijay Kumar maintained an Outperform rating on Illumina and raised the price target to $200 from $155, reflecting confidence in the genomics firm's growth. This move aligns with similar bullish sentiment from Piper Sandler and Guggenheim, both of which also have a $200 price target, while Bernstein holds a Market Perform rating at $185.
*this image is generated using AI for illustrative purposes only.
Evercore ISI Group analyst Vijay Kumar has maintained an Outperform rating on Illumina (NASDAQ: ILMN) and raised the price target to $200 from $155. The adjustment signals increased confidence in the genomics company's valuation and growth trajectory.
Illumina specializes in providing tools and systems for genetic analysis within the genomics sector. The new price target of $200 offers investors a revised benchmark for assessing the stock's potential upside against current trading levels.
This update follows a separate rating action by Piper Sandler analyst David Westenberg, who maintained an Overweight rating with a price target of $200. Additionally, Guggenheim analyst Subbu Nambi has a Buy rating with a price target of $200, while Bernstein analyst Eve Burstein assigned a Market Perform rating with a price target of $185.
| Firm | Analyst | Rating | Price Target |
|---|---|---|---|
| Evercore ISI Group | Vijay Kumar | Outperform | $200 |
| Piper Sandler | David Westenberg | Overweight | $200 |
| Guggenheim | Subbu Nambi | Buy | $200 |
| Bernstein | Eve Burstein | Market Perform | $185 |
What specific catalysts does Evercore ISI anticipate will drive Illumina's stock to the new $200 price target?
How might the consensus among multiple analysts at the $200 level influence institutional investor sentiment toward Illumina?
What impact could recent advancements in genetic analysis technology have on Illumina's competitive positioning?
15
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
